is the fda banning semaglutide issues warning about some compounded versions of for diabetes, weight loss Compounded "semaglutide" is not FDA-approved

Eli Lillys orforglipron continues to advance but has not yet reached benchmark weight loss efficacy

Each of those steps represents a potential failure point

A 2023 study published in the Journal of Clinical Endocrinology and Metabolism found that GLP-1 receptor agonist therapy in women with obesity and insulin resistance produced significant improvements in androgen levels, menstrual regularity, and metabolic markers, with effects most pronounced in women with baseline hyperinsulinemia, underscoring how tightly GLP-1 mechanisms are connected to broader hormonal function in women

Alvanzo spent twelve years as faculty in the Divisions of General Internal Medicine and Addiction Medicine at Johns Hopkins University School of Medicine where she held a variety of clinical leadership roles, including Associate Medical Director of Addiction Treatment Services and the Center for Addiction and Pregnancy and Medical Director of the Broadway Center for Addiction, comprehensive, outpatient substance use disorder treatment (SUD) programs on the Johns Hopkin Bayview and Johns Hopkins Hospital campuses, respectively

Specifically, thyroid function should be rechecked 6-8 weeks after starting or titrating GLP-1 therapy, after significant weight loss, or after any levothyroxine dose change